Effect of Huganning tablet on nonalcoholic steatohepatitis in rats

Hua WAN,Guo-sheng YANG,Ying-hong TAO,Hong-li XI,Xue-jing WANG,Xiao-yuan XU

DOI: https://doi.org/10.3760/cma.j.issn.1673-4777.2010.08.017

2010-01-01

Abstract:Objective To investigate the protective effect and mechanism of Huganning tablet on rat model of nonalcoholic steatohepatitis( NASH). Methods After one week of a standard diet 39 male SD rats were random-ly divided into the normal control group(n =9) and the experimental group(n =30). The normal control group rats were fed with a standard diet, while those of the experimental group had a high-fat diet. After 10 weeks 9 rats were sacrificed to verify whether the model was established successfully. Then the experimental group was randomly sub-divided into five groups :Group Z(n =5) with a high-fat diet and gastric with saline, GroupY(n=5) with a stand-ard diet and gastric with saline, GroupA(n=5), Group B(n=5) and Group C(n =5) with a standard diet and gastrically infused with the Huganning Tablet solution of high-dosage (700 mg/kg/d), middle-dosage (350 mg/kg/d) and low-dosage(175 mg/kg/d), respectively. Four weeks later, all rats were sacrificed. Blood samples were collected to measure serum ALT, AST,TG,TC, LDL-C, GLU, SOD and MDA. Tissue samples were duly taken for histopathological examination and measurement of tissue TC, TG, LDL-C and MDA levels. Results There were lower levels of visceral adiposity ratio in Group B and Group C compared with Group Y( P <0. 05 ). There were low-er levels of serum AST, TC, GLU and liver tissue TC in Group A compared to Group Y(P<0.05). A significant increase was found in the serum SOD levels in Group A compared to Group Y( P < 0. 05). A significant reduction was observed in Group A in the hepatic steatosis, the grade of inflammation and the stage of fibrosis compared to Group Y and Group Z ( P < 0. 05). Conclusions Huganning Tablet seems to be effective in attenuating hepatic damage in the NASH model induced by a high-fat diet, which may become a potential drug for NASH treatment in the future.